Malignancy after renal transplantation in the new era of immunosuppression

Annals of Transplantation

Volumn 16, Issue 2, 2011, Pages 14-18

  Watorek, Ewa ^a   Boratyńska, Maria ^a   Smolska, Danuta ^a   Patrzałek, Dariusz ^a   Klinger, Marian ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Immunosuppression; Kidney transplantation; Malignancy

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; RAPAMYCIN; TACROLIMUS;

ABDOMINAL RADIOGRAPHY; ADULT; ARTICLE; BLADDER CANCER; CANCER SCREENING; CHRONIC GLOMERULONEPHRITIS; CHRONIC KIDNEY DISEASE; CHRONIC PYELONEPHRITIS; CLINICAL ARTICLE; DIABETIC NEPHROPATHY; DIGITAL RECTAL EXAMINATION; FEMALE; GRAFT RECIPIENT; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CANCER; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; LYMPH NODE BIOPSY; LYMPHOPROLIFERATIVE DISEASE; MALE; MAMMOGRAPHY; NONHODGKIN LYMPHOMA; OCCULT BLOOD; PAPANICOLAOU TEST; PELVIC EXAMINATION; PREGNANCY TOXEMIA; PROSTATE CANCER; RETROSPECTIVE STUDY; SKIN EXAMINATION; THORAX RADIOGRAPHY; URINARY TRACT TUMOR;

EID: 79960077315     PISSN: 14259524     EISSN: None     Source Type: Journal    
DOI: 10.12659/aot.881859     Document Type: Article

References (21)

1. United Network of Organ Sharing (UNOS); Organ procurement and transplant network (OPTN) Date as of June 1, 2005. Available at www.optn.org
2. Buell JF, Gross TG, Woodle ES: Malignancy after Transplantation. Transplantation, 2005; 80: S254-64
3. Zmonarski SC, Boratyńska M, Puziewicz-Zmonarska A et al: Kaposi's sarcoma in renal transplant recipients. Ann Transplant, 2005; 10: 59-65
4. Khedmat H, Alavian S, Taheri S: Significance of Epstein-Barr virus infection in the outcome of renal transplant patients with lymphoproliferative disorders. Ann Transplant, 2010; 15: 40-44
5. Swan PF, Waters TR, Moulton DC et al: Role of postreplicative DNA mismatch repair in the cytotoxic action of thioguanine. Science, 1996; 273: 1109-11
6. Guba M, Graeb C, Jauch KW, Geissler EK: Pro- and anti-cancer effects of immunosuppressive gents used in organ transplantation. Transplantation, 2004; 77: 1777-82
7. Boratyńska M, Watorek E, Falkiewicz K, Banasik M: Increased plasma TGF-beta 1 level in patient with salivary gland carcinoma after renal transplantation. Ann Transplant, 2005; 10: 16-19
8. Cherikh WS, Kauffman HM, McBride MA et al: Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation, 2003; 76: 1289-93
9. Birkeland SA, Lokkegaard H, Storm HH: Cancer risk in patients on dialysis and after renal transplantation. Lancet, 2000; 355: 1886-87
10. Hartevelt MM, Bavinck JN, Kootte AM et al: Incidence of skin cancer after renal transplantation in the Netherlads. Transplantation, 1990; 49: 506-9
11. Penn I: Cancer in renal transplant recipients. Adv Renal Replace Ther, 2000; 7: 147-56
12. Khedmat H, Taheri S: Late onset Post Transplantation Lymphoproliferative Disorders: Analysis of International Data from 5 Studies Ann Transplant, 2009; 14: 80-85
13. R Development Core Team R: A language and environment for statistical computing. R foundation for statistical computing, Vienna, Austria, 2007, ISBN 3-900051-07-0 http://www.R-project.org
14. Dantal J, Pohanka E: Malignancies in renal transplantation: an unmet medical need. Nephrol. Dial. Transplant, 2007; 22(Suppl.1) i4-10
15. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C: Cancer after kidney transplantation in the United States. Am J Transplnt, 2004; 4: 905-13
16. Bustami RT, Ojo AO, Wolfe RA et al: Immunosupression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients. Am J Transplant, 2004; 4: 87-93
17. Samhan M, Al-Mousawi M, Donia F et al: Malignancy in Renal Recipients. Transplantation Proc, 2005; 37: 3068-70
18. Penn I: The incidence of malignancies in transplant recipients. Transplantation Proc, 1975; 7: 323-26
19. Tremblay F, Fernandes M, Habbab F et al: Malignancy after renal transplantation: incidence and role of type of immunosuppression. Ann Surg Oncol, 2002; 9: 785-88
20. Boratyńska M, Smolska D: Inhibition of mTOR by sirolimus induces remission of post-transplant lymphoproliferative disorders. Transpl Int, 2008; 21: 605-8
21. Yakupoqlu YK, Buell JF, Woodle S, Kahan BD: Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transpl Proc, 2006; 2: 358-61